Massimo Morfini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/748968/publications.pdf

Version: 2024-02-01

		218677	223800
61	2,224	26	46
papers	citations	h-index	g-index

61	61	61	1225
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	European Study on Orthopaedic Status of haemophilia patients with inhibitors. Haemophilia, 2007, 13, 606-612.	2.1	192
2	Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates. American Journal of Hematology, 1992, 39, 228-230.	4.1	166
3	Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood, 2012, 120, 2405-2411.	1.4	160
4	Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrates. Journal of Medical Virology, 1988, 25, 165-170.	5.0	109
5	Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. Blood, 2009, 114, 779-784.	1.4	108
6	Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization. Transfusion, 1997, 37, 517-522.	1.6	96
7	The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype. Haematologica, 2008, 93, 722-728.	3.5	95
8	The Design and Analysis of Half-Life and Recovery Studies for Factor VIII and Factor IX. Thrombosis and Haemostasis, 1991, 66, 384-386.	3.4	90
9	Practical aspects of extended half-life products for the treatment of haemophilia. Therapeutic Advances in Hematology, 2018, 9, 295-308.	2.5	85
10	Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficultâ€toâ€treat patients. European Journal of Haematology, 2019, 102, 111-122.	2.2	78
11	Pain and pain management in haemophilia. Blood Coagulation and Fibrinolysis, 2016, 27, 845-854.	1.0	66
12	Comparative pharmacokinetics of <scp>rVIII</scp>â€SingleChain and octocog alfa (Advate^{Â®}) in patients with severe haemophilia A. Haemophilia, 2016, 22, 730-738.	2.1	52
13	ReFactoÂ®1and AdvateÂ®2: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A. Haemophilia, 2007, 13, 124-130.	2.1	49
14	Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATEÂ®) - an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A. Haemophilia, 2011, 17, 854-859.	2.1	47
15	Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future. Blood Transfusion, 2014, 12, 314-9.	0.4	46
16	TT virus contaminates first-generation recombinant factor VIII concentrates. Blood, 2001, 98, 2571-2573.	1.4	39
17	Pharmacokinetics of factor VIII and factor IX. Haemophilia, 2003, 9, 94-100.	2.1	37
18	Evaluation of Prophylactic Replacement Therapy in Haemophilia B. Scandinavian Journal of Haematology, 1976, 16, 41-47.	0.0	36

#	Article	IF	Citations
19	Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates. Thrombosis and Haemostasis, 2017, 117, 1023-1030.	3.4	36
20	Paediatric haemophilia with inhibitors: existing management options, treatment gaps and unmet needs. Haemophilia, 2009, 15, 983-989.	2.1	35
21	Intra-articular injections of hyaluronic acid induce positive clinical effects in knees of patients affected by haemophilic arthropathy. Knee, 2013, 20, 36-39.	1.6	35
22	Angiogenesis is increased in advanced haemophilic joint disease and characterised by normal pericyte coverage. European Journal of Haematology, 2014, 92, 256-262.	2.2	34
23	Comparative pharmacokinetics of two extended halfâ€life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?. Journal of Thrombosis and Haemostasis, 2019, 17, 1085-1096.	3.8	34
24	A modular total knee arthroplasty in haemophilic arthropathy. Knee, 2007, 14, 264-268.	1.6	33
25	Prospective study of the evaluation of hepatitis C virus infectivity in a high-purity, solvent/detergent-treated factor VIII concentrate: parallel evaluation of other markers for lipid-enveloped and non-lipid- enveloped viruses. The Ad Hoc Study Group of the Fondazione dell'Emofilia. Transfusion, 1993, 33, 814-818.	1.6	31
26	Viscosupplementation in haemophilic arthropathy: a longâ€term followâ€up study. Haemophilia, 2012, 18, e210-4.	2.1	26
27	The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Thrombosis and Haemostasis, 1991, 66, 384-6.	3.4	25
28	Pharmacokinetic properties of <scp>IB</scp>1001, an investigational recombinant factor <scp>IX</scp>, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis. Haemophilia, 2012, 18, 881-887.	2.1	23
29	Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Blood Transfusion, 2020, 18, 143-151.	0.4	22
30	Accuracy of FVIII:C assay by one-stage method can be improved using hemophilic plasma as diluent. Journal of Thrombosis and Haemostasis, 2006, 4, 828-833.	3.8	21
31	Singleâ€dose pharmacokinetics of Factor IX evaluated by modelâ€independent methods. European Journal of Haematology, 1987, 39, 426-433.	2.2	21
32	Switching treatments in haemophilia: is there a risk of inhibitor development?. European Journal of Haematology, 2015, 94, 284-289.	2.2	21
33	Recent Advances in the Treatment of Hemophilia: A Review. Biologics: Targets and Therapy, 2021, Volume 15, 221-235.	3.2	21
34	Population pharmacokinetics of a new longâ€acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B. Journal of Thrombosis and Haemostasis, 2016, 14, 2132-2140.	3.8	18
35	Correlation between <scp>FIX</scp> genotype and pharmacokinetics of Nonacog alpha according to a multicentre Italian study. Haemophilia, 2016, 22, 537-542.	2.1	17
36	Low risk of transmission of the human immunodeficiency virus by a solvent-detergent-treated commercial factor VIII concentrate. Journal of Medical Virology, 1992, 36, 71-74.	5.0	16

#	Article	IF	Citations
37	Novel coagulation factor concentrates: Issues relating to their clinical implementation and pharmacokinetic assessment for optimal prophylaxis in haemophilia patients. Haemophilia, 2013, 19, 481-486.	2.1	16
38	Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates. Journal of Thrombosis and Haemostasis, 2019, 17, 1288-1296.	3.8	15
39	Practical considerations for nonfactorâ€replacement therapies in the treatment of haemophilia with inhibitors. Haemophilia, 2021, 27, 340-350.	2.1	15
40	Emerging drugs for the treatment of hemophilia A and B. Expert Opinion on Emerging Drugs, 2016, 21, 301-313.	2.4	14
41	Hepatitis-Free Interval After Clotting Factor Therapy in First Infused Haemophiliacs. Thrombosis and Haemostasis, 1986, 56, 268-270.	3.4	14
42	Pharmacokinetic studies: international guidelines for the conduct and interpretation of such studies. Haemophilia, 2006, 12, 6-11.	2.1	12
43	Safety of recombinant coagulation factors in treating hemophilia. Expert Opinion on Drug Safety, 2019, 18, 75-85.	2.4	12
44	Joint replacement for the management of haemophilic arthropathy in patients with inhibitors: A longâ€term experience at a single Haemophilia centre. Haemophilia, 2021, 27, e93-e101.	2.1	12
45	Inâ€patient rehabilitation in haemophilic subjects with total knee arthroplasty. Haemophilia, 2011, 17, e999-e1004.	2.1	11
46	The History of Clotting Factor Concentrates Pharmacokinetics. Journal of Clinical Medicine, 2017, 6, 35.	2.4	11
47	Pharmacokinetic-based prediction of real-life dosing of extended half-life clotting factor concentrates on hemophilia. Therapeutic Advances in Hematology, 2018, 9, 149-162.	2.5	11
48	Patient satisfaction and acceptability of an on-demand and on-prophylaxis device for factor VIII delivery in patients with hemophilia A . Patient Preference and Adherence, 2019, Volume 13, 233-240.	1.8	11
49	The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A. Thrombosis and Haemostasis, 2022, 122, 715-725.	3.4	9
50	F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes. Journal of Thrombosis and Haemostasis, 2022, 20, 69-81.	3.8	9
51	Outcome measures for adult and pediatric hemophilia patients with inhibitors. European Journal of Haematology, 2017, 99, 103-111.	2.2	8
52	The availability of new drugs for hemophilia treatment. Expert Review of Clinical Pharmacology, 2020, 13, 721-738.	3.1	5
53	In vitro characteristics of highly purified factor VIII concentrates. Annals of Hematology, 1991, 63, 123-125.	1.8	4
54	Riskâ€sharing approach for managing factor VIIa reimbursement in haemophilia patients with inhibitors. Haemophilia, 2010, 16, 548-550.	2.1	3

#	Article	IF	Citations
55	Combination of CLEC4M rs868875 G-Carriership and ABO O Genotypes May Predict Faster Decay of FVIII Infused in Hemophilia A Patients. Journal of Clinical Medicine, 2022, 11, 733.	2.4	3
56	Pharmacokinetic and safety considerations when switching from standard to extended half-life clotting factor concentrates in hemophilia. Expert Review of Hematology, 2019, 12, 883-892.	2.2	2
57	Pharmacokinetics of a new human plasmaâ€derived double virus inactivated and nanofiltered factor IX concentrate in previously treated severe or moderately severe haemophilia B patients. Haemophilia, 2019, 25, e364-e367.	2.1	2
58	Hepatitis-free interval after clotting factor therapy in first infused haemophiliacs. Thrombosis and Haemostasis, 1986, 56, 268-70.	3.4	2
59	Non-Compartment and compartmental pharmacokinetics, efficacy, and safety of Kedrion FIX concentrate. European Journal of Pharmaceutical Sciences, 2020, 153, 105485.	4.0	1
60	Pharmacokinetic characteristics of the triple inactivated plasma-derived Kedrion FIX concentrate: data from the KB037 clinical trial. Data in Brief, 2020, 32, 106164.	1.0	1
61	A Practical, One Clinic Visit, Population Pharmacokinetic (PK) Protocol for Generation of PK Profiles in Subjects with Severe Hemophilia a. Blood, 2018, 132, 2480-2480.	1.4	1